[Lentigo maligna treated with 5% imiquimod cream].
Lentigo maligna (LM) is considered to be an in-situ stage of lentigo maligna melanoma. Clinically, it presents as a pigmented macule, irregular in shape and tone. 30% to 35% of untreated lentigo malignas can progress into lentigo maligna melanoma. The treatment of choice for this pathology is surgical excision with margins of 0.5 cm. of clinically normal skin around the lesion, or Mohs microsurgery. Imiquimod is a topical immunomodulator that stimulates both acquired and innate immunity. We present the case of a patient with LM, treated with 5% imiquimod cream, with an excellent therapeutic response.
Servicio de Dermatología, Hospital Civil, Complejo Hospitalario Carlos Haya, Málaga, Spain. Trinim@hotmail.com
Trinidad
T
Martín
Antonio
A
Ojeda
Silvestre
S
Martínez
Angel
A
Vera
D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004304:Dosage Forms; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy*; D000077271:Imiquimod; D008875:Middle Aged; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy*
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D004304:Dosage Forms; D000077271:Imiquimod